Cannara Biotech Stock Performance
| LOVE Stock | CAD 0.78 0.08 11.43% |
On a scale of 0 to 100, Cannara Biotech holds a performance score of 7. The firm shows a Beta (market volatility) of -0.0053, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cannara Biotech are expected to decrease at a much lower rate. During the bear market, Cannara Biotech is likely to outperform the market. Please check Cannara Biotech's sortino ratio, maximum drawdown, and the relationship between the total risk alpha and treynor ratio , to make a quick decision on whether Cannara Biotech's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cannara Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Cannara Biotech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2023-02-13 |
1 | Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024 - Yahoo Finance | 12/12/2024 |
| Begin Period Cash Flow | 12.1 M |
Cannara |
Cannara Biotech Relative Risk vs. Return Landscape
If you would invest 61.00 in Cannara Biotech on October 1, 2024 and sell it today you would earn a total of 17.00 from holding Cannara Biotech or generate 27.87% return on investment over 90 days. Cannara Biotech is generating 0.6003% of daily returns assuming 6.4357% volatility of returns over the 90 days investment horizon. Simply put, 57% of all stocks have less volatile historical return distribution than Cannara Biotech, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cannara Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannara Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cannara Biotech, and traders can use it to determine the average amount a Cannara Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0933
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LOVE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.44 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Cannara Biotech is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cannara Biotech by adding it to a well-diversified portfolio.
Cannara Biotech Fundamentals Growth
Cannara Stock prices reflect investors' perceptions of the future prospects and financial health of Cannara Biotech, and Cannara Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cannara Stock performance.
| Return On Equity | 0.0678 | ||||
| Return On Asset | 0.0378 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 111.92 M | ||||
| Shares Outstanding | 90.02 M | ||||
| Price To Book | 0.80 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 57.26 M | ||||
| Gross Profit | 17.33 M | ||||
| EBITDA | 14.29 M | ||||
| Net Income | 6.95 M | ||||
| Cash And Equivalents | 5.56 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 5.97 M | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 2.95 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | 5.44 M | ||||
| Earnings Per Share | 0.07 X | ||||
| Market Capitalization | 70.21 M | ||||
| Total Asset | 141.52 M | ||||
| Retained Earnings | (19.34 M) | ||||
| Working Capital | 30.51 M | ||||
About Cannara Biotech Performance
Evaluating Cannara Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cannara Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cannara Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 281.49 | 201.94 | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.08 |
Things to note about Cannara Biotech performance evaluation
Checking the ongoing alerts about Cannara Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cannara Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cannara Biotech is way too risky over 90 days horizon | |
| Cannara Biotech has some characteristics of a very speculative penny stock | |
| Cannara Biotech appears to be risky and price may revert if volatility continues | |
| Cannara Biotech is unlikely to experience financial distress in the next 2 years | |
| About 49.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024 - Yahoo Finance |
- Analyzing Cannara Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cannara Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Cannara Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cannara Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cannara Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cannara Biotech's stock. These opinions can provide insight into Cannara Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.